Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P G Gill

Showing results (81-90 of 83) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 83 results.
The Medical Journal of Australia|May 14, 1983
Chemotherapy of squamous cell cancer of the head and neckP G Gill, J D Hains, P Iyer, et al.
Melanoma Research|April 1, 1993
Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trialD B Thomson, M Adena, G R McLeod, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trialN Zdenkowski, J F Forbes, F M Boyle, et al.
Pageof 9

Showing results (81-90 of 83) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 83 results.
The Medical Journal of Australia|May 14, 1983
Chemotherapy of squamous cell cancer of the head and neckP G Gill, J D Hains, P Iyer, et al.
Melanoma Research|April 1, 1993
Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trialD B Thomson, M Adena, G R McLeod, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trialN Zdenkowski, J F Forbes, F M Boyle, et al.
Pageof 9